Cargando…

The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology

Alzheimer Disease (AD) constitutes a major global healthcare problem. Standard AD pharmacotherapies offer only modest transient cognitive and behavioral benefits. Aducanumab, an amyloid monoclonal antibody, was the first disease modifying agent to be approved for AD treatment. However, concerns abou...

Descripción completa

Detalles Bibliográficos
Autores principales: Tayeb, Haythum O., Khallaf, Roaa A., Muayqil, Taim A., Alkeridy, Walid A., Alibrahim, Fawwaz S., Alfaify, Omar A., Qadi, Najeeb, Tarazi, Frank I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Riyadh : Armed Forces Hospital 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155484/
https://www.ncbi.nlm.nih.gov/pubmed/37045461
http://dx.doi.org/10.17712/nsj.2023.2.20220133
_version_ 1785036338731417600
author Tayeb, Haythum O.
Khallaf, Roaa A.
Muayqil, Taim A.
Alkeridy, Walid A.
Alibrahim, Fawwaz S.
Alfaify, Omar A.
Qadi, Najeeb
Tarazi, Frank I.
author_facet Tayeb, Haythum O.
Khallaf, Roaa A.
Muayqil, Taim A.
Alkeridy, Walid A.
Alibrahim, Fawwaz S.
Alfaify, Omar A.
Qadi, Najeeb
Tarazi, Frank I.
author_sort Tayeb, Haythum O.
collection PubMed
description Alzheimer Disease (AD) constitutes a major global healthcare problem. Standard AD pharmacotherapies offer only modest transient cognitive and behavioral benefits. Aducanumab, an amyloid monoclonal antibody, was the first disease modifying agent to be approved for AD treatment. However, concerns about its efficacy and side effects led regulatory institutions around the world to restrict its use. Lecanemab was the second amyloid antibody to receive accelerated approval for use in early AD. This review and consensus statement was prepared by the Saudi Chapter of Cognitive and Behavioral Neurology to review the current developments in AD immunotherapies from a Saudi perspective. We outline recommendations with regards to offering aducanumab and other future immunotherapies to Saudi AD patients. We describe resources, infrastructure, research, and clinical practice changes that must be attained to transform the patient journey and clinical pathways of AD in Saudi Arabia to enable offering AD immunotherapies in Saudi Arabia.
format Online
Article
Text
id pubmed-10155484
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Riyadh : Armed Forces Hospital
record_format MEDLINE/PubMed
spelling pubmed-101554842023-05-04 The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology Tayeb, Haythum O. Khallaf, Roaa A. Muayqil, Taim A. Alkeridy, Walid A. Alibrahim, Fawwaz S. Alfaify, Omar A. Qadi, Najeeb Tarazi, Frank I. Neurosciences (Riyadh) Clinical Practice Guideline Alzheimer Disease (AD) constitutes a major global healthcare problem. Standard AD pharmacotherapies offer only modest transient cognitive and behavioral benefits. Aducanumab, an amyloid monoclonal antibody, was the first disease modifying agent to be approved for AD treatment. However, concerns about its efficacy and side effects led regulatory institutions around the world to restrict its use. Lecanemab was the second amyloid antibody to receive accelerated approval for use in early AD. This review and consensus statement was prepared by the Saudi Chapter of Cognitive and Behavioral Neurology to review the current developments in AD immunotherapies from a Saudi perspective. We outline recommendations with regards to offering aducanumab and other future immunotherapies to Saudi AD patients. We describe resources, infrastructure, research, and clinical practice changes that must be attained to transform the patient journey and clinical pathways of AD in Saudi Arabia to enable offering AD immunotherapies in Saudi Arabia. Riyadh : Armed Forces Hospital 2023-04 /pmc/articles/PMC10155484/ /pubmed/37045461 http://dx.doi.org/10.17712/nsj.2023.2.20220133 Text en Copyright: © Neurosciences https://creativecommons.org/licenses/by-nc/3.0/Neurosciences is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work.
spellingShingle Clinical Practice Guideline
Tayeb, Haythum O.
Khallaf, Roaa A.
Muayqil, Taim A.
Alkeridy, Walid A.
Alibrahim, Fawwaz S.
Alfaify, Omar A.
Qadi, Najeeb
Tarazi, Frank I.
The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology
title The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology
title_full The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology
title_fullStr The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology
title_full_unstemmed The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology
title_short The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology
title_sort future of alzheimer disease immunotherapies in saudi arabia: consensus statement of the saudi chapter of cognitive and behavioral neurology
topic Clinical Practice Guideline
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155484/
https://www.ncbi.nlm.nih.gov/pubmed/37045461
http://dx.doi.org/10.17712/nsj.2023.2.20220133
work_keys_str_mv AT tayebhaythumo thefutureofalzheimerdiseaseimmunotherapiesinsaudiarabiaconsensusstatementofthesaudichapterofcognitiveandbehavioralneurology
AT khallafroaaa thefutureofalzheimerdiseaseimmunotherapiesinsaudiarabiaconsensusstatementofthesaudichapterofcognitiveandbehavioralneurology
AT muayqiltaima thefutureofalzheimerdiseaseimmunotherapiesinsaudiarabiaconsensusstatementofthesaudichapterofcognitiveandbehavioralneurology
AT alkeridywalida thefutureofalzheimerdiseaseimmunotherapiesinsaudiarabiaconsensusstatementofthesaudichapterofcognitiveandbehavioralneurology
AT alibrahimfawwazs thefutureofalzheimerdiseaseimmunotherapiesinsaudiarabiaconsensusstatementofthesaudichapterofcognitiveandbehavioralneurology
AT alfaifyomara thefutureofalzheimerdiseaseimmunotherapiesinsaudiarabiaconsensusstatementofthesaudichapterofcognitiveandbehavioralneurology
AT qadinajeeb thefutureofalzheimerdiseaseimmunotherapiesinsaudiarabiaconsensusstatementofthesaudichapterofcognitiveandbehavioralneurology
AT tarazifranki thefutureofalzheimerdiseaseimmunotherapiesinsaudiarabiaconsensusstatementofthesaudichapterofcognitiveandbehavioralneurology
AT tayebhaythumo futureofalzheimerdiseaseimmunotherapiesinsaudiarabiaconsensusstatementofthesaudichapterofcognitiveandbehavioralneurology
AT khallafroaaa futureofalzheimerdiseaseimmunotherapiesinsaudiarabiaconsensusstatementofthesaudichapterofcognitiveandbehavioralneurology
AT muayqiltaima futureofalzheimerdiseaseimmunotherapiesinsaudiarabiaconsensusstatementofthesaudichapterofcognitiveandbehavioralneurology
AT alkeridywalida futureofalzheimerdiseaseimmunotherapiesinsaudiarabiaconsensusstatementofthesaudichapterofcognitiveandbehavioralneurology
AT alibrahimfawwazs futureofalzheimerdiseaseimmunotherapiesinsaudiarabiaconsensusstatementofthesaudichapterofcognitiveandbehavioralneurology
AT alfaifyomara futureofalzheimerdiseaseimmunotherapiesinsaudiarabiaconsensusstatementofthesaudichapterofcognitiveandbehavioralneurology
AT qadinajeeb futureofalzheimerdiseaseimmunotherapiesinsaudiarabiaconsensusstatementofthesaudichapterofcognitiveandbehavioralneurology
AT tarazifranki futureofalzheimerdiseaseimmunotherapiesinsaudiarabiaconsensusstatementofthesaudichapterofcognitiveandbehavioralneurology